Market Cap 1.60B
Revenue (ttm) 10.59M
Net Income (ttm) -68.99M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -651.46%
Debt to Equity Ratio 0.00
Volume 1,197,300
Avg Vol 903,094
Day's Range N/A - N/A
Shares Out 59.11M
Stochastic %K 7%
Beta 3.23
Analysts Strong Sell
Price Target $91.50

Latest News on JANX

Best-Performing Stocks Of 2024

Jan 2, 2025, 11:46 PM EST - 3 months ago

Best-Performing Stocks Of 2024

APP BYRN CADL DAVE INOD LUNR MSTR


Janux Therapeutics Announces Proposed Public Offering

Dec 3, 2024, 4:01 PM EST - 4 months ago

Janux Therapeutics Announces Proposed Public Offering


Janux Therapeutics Announces Updates to Board of Directors

Jul 22, 2024, 4:01 PM EDT - 9 months ago

Janux Therapeutics Announces Updates to Board of Directors


Janux Therapeutics (JANX) stock has gone parabolic: what next?

Apr 30, 2024, 12:06 AM EDT - 1 year ago

Janux Therapeutics (JANX) stock has gone parabolic: what next?


Janux Therapeutics: A Prime Target In Cancer Care's M&A Game

Apr 11, 2024, 9:00 AM EDT - 1 year ago

Janux Therapeutics: A Prime Target In Cancer Care's M&A Game


Janux Therapeutics Appoints Winston Kung to Board of Directors

Sep 22, 2022, 6:00 AM EDT - 2 years ago

Janux Therapeutics Appoints Winston Kung to Board of Directors